165 related articles for article (PubMed ID: 32386450)
21. The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients.
Luukkonen PK; Qadri S; Lehtimäki TE; Juuti A; Sammalkorpi H; Penttilä AK; Hakkarainen A; Orho-Melander M; Arola J; Yki-Järvinen H
J Clin Endocrinol Metab; 2021 Jan; 106(1):e300-e315. PubMed ID: 33064150
[TBL] [Abstract][Full Text] [Related]
22. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
Rametta R; Ruscica M; Dongiovanni P; Macchi C; Fracanzani AL; Steffani L; Fargion S; Magni P; Valenti L
Eur J Clin Invest; 2014 Jul; 44(7):627-33. PubMed ID: 24828988
[TBL] [Abstract][Full Text] [Related]
23. PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients.
Liu ZT; Chen TC; Lu XX; Cheng J; Xie HY; Zhou L; Zheng SS
World J Gastroenterol; 2015 Sep; 21(34):10054-6. PubMed ID: 26379412
[TBL] [Abstract][Full Text] [Related]
24. PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease.
Sookoian S; Pirola CJ
World J Gastroenterol; 2012 Nov; 18(42):6018-26. PubMed ID: 23155331
[TBL] [Abstract][Full Text] [Related]
25. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
[TBL] [Abstract][Full Text] [Related]
26. PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress.
Carpino G; Pastori D; Baratta F; Overi D; Labbadia G; Polimeni L; Di Costanzo A; Pannitteri G; Carnevale R; Del Ben M; Arca M; Violi F; Angelico F; Gaudio E
Sci Rep; 2017 Nov; 7(1):15756. PubMed ID: 29150621
[TBL] [Abstract][Full Text] [Related]
27. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
28. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.
Xia MF; Ling Y; Bian H; Lin HD; Yan HM; Chang XX; Li XM; Ma H; Wang D; Zhang LS; Wang SS; Wu BJ; He WY; Zhao NQ; Gao X
Aliment Pharmacol Ther; 2016 Mar; 43(5):631-42. PubMed ID: 26765961
[TBL] [Abstract][Full Text] [Related]
29. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
Unalp-Arida A; Ruhl CE
Hepatology; 2020 Mar; 71(3):820-834. PubMed ID: 31705824
[TBL] [Abstract][Full Text] [Related]
30. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
[TBL] [Abstract][Full Text] [Related]
31. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
[TBL] [Abstract][Full Text] [Related]
32. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.
Chen Y; Yan X; Xu X; Yuan S; Xu F; Liang H
Endocrine; 2020 Dec; 70(3):517-525. PubMed ID: 32862405
[TBL] [Abstract][Full Text] [Related]
33. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis.
Li JZ; Huang Y; Karaman R; Ivanova PT; Brown HA; Roddy T; Castro-Perez J; Cohen JC; Hobbs HH
J Clin Invest; 2012 Nov; 122(11):4130-44. PubMed ID: 23023705
[TBL] [Abstract][Full Text] [Related]
34. Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression.
Wieser V; Adolph TE; Enrich B; Moser P; Moschen AR; Tilg H
Liver Int; 2017 Feb; 37(2):299-306. PubMed ID: 27514759
[TBL] [Abstract][Full Text] [Related]
35. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2318619121. PubMed ID: 38657050
[TBL] [Abstract][Full Text] [Related]
36. Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
Tilson SG; Morell CM; Lenaerts AS; Park SB; Hu Z; Jenkins B; Koulman A; Liang TJ; Vallier L
Hepatology; 2021 Dec; 74(6):2998-3017. PubMed ID: 34288010
[TBL] [Abstract][Full Text] [Related]
37. Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity.
Marzuillo P; Di Sessa A; Guarino S; Capalbo D; Umano GR; Pedullà M; La Manna A; Cirillo G; Miraglia Del Giudice E
Pediatr Obes; 2019 Oct; 14(10):e12539. PubMed ID: 31184438
[TBL] [Abstract][Full Text] [Related]
38. Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction.
Mantovani A; Pelusi S; Margarita S; Malvestiti F; Dell'Alma M; Bianco C; Ronzoni L; Prati D; Targher G; Valenti L
Aliment Pharmacol Ther; 2023 May; 57(10):1093-1102. PubMed ID: 36947711
[TBL] [Abstract][Full Text] [Related]
39. [Influence of leptin receptor gene K109R polymorphism on the risk of nonalcoholic fatty liver disease and its interaction with PNPLA3 I148M polymorphism].
An BQ; Jiang M; Cheng YT; Yuan C; Lu LL; Xin YN; Xuan SY
Zhonghua Gan Zang Bing Za Zhi; 2016 May; 24(5):358-62. PubMed ID: 27470889
[TBL] [Abstract][Full Text] [Related]
40. Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
Murray JK; Long J; Liu L; Singh S; Pruitt D; Ollmann M; Swearingen E; Hardy M; Homann O; Wu B; Holder JR; Sham K; Herberich B; Lo MC; Dou H; Shkumatov A; Florio M; Rulifson IC
Nucleic Acid Ther; 2021 Oct; 31(5):324-340. PubMed ID: 34297902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
